Register entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 2 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 2.
| Dosage form | NDCs |
|---|---|
| solution | 1 |
| suspension | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| tirzepatide pharma | 2 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Zeptide Aspart | solution | 87994-013DRUG FOR FURTHER PROCESSING |
| - | Zeptide Insulin Cartridge Blend | suspension | 87994-011DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is Tirzepatide Pharma FDA approved?
- Tirzepatide Pharma holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Tirzepatide Pharma make?
- 2 products are listed under Tirzepatide Pharma in the openFDA NDC Directory, most often as solution; suspension. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.